{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:20:44Z","timestamp":1794738044777,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01373-0","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:49:29Z","timestamp":1743202169000},"page":"1320-1334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles"],"prefix":"10.1038","volume":"9","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4386-3992","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-2934","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","volume":"181","author":"L Fugger","year":"2020","unstructured":"Fugger, L., Jensen, L. T. & Rossjohn, J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell 181, 63\u201380 (2020).","journal-title":"Cell"},{"key":"1373_CR2","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878\u20131890 (2023).","journal-title":"Lancet"},{"key":"1373_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney, E. F., Lee, J. C., Jayne, D. R., Lyons, P. A. & Smith, K. G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612\u2013616 (2015).","journal-title":"Nature"},{"key":"1373_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/d41573-021-00137-0","volume":"20","author":"M Cully","year":"2021","unstructured":"Cully, M. T cell-regulating therapies for autoimmune diseases take FDA rejection in stride. Nat. Rev. Drug Discov. 20, 655\u2013657 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1373_CR5","first-page":"526","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard, A. PD1 agonist antibody passes first phase II trial for autoimmune disease. Nat. Rev. Drug Discov. 22, 526 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1373_CR6","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","volume":"5","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288\u20131305 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1373_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","volume":"19","author":"NM Edner","year":"2020","unstructured":"Edner, N. M., Carlesso, G., Rush, J. S. & Walker, L. S. K. Targeting co-stimulatory molecules in autoimmune disease. Nat. Rev. Drug Discov. 19, 860\u2013883 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1373_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692\u20131698 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1373_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41565-020-00810-2","volume":"16","author":"A Cifuentes-Rius","year":"2021","unstructured":"Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R. & Voelcker, N. H. Inducing immune tolerance with dendritic cell-targeting nanomedicines. Nat. Nanotechnol. 16, 37\u201346 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1373_CR10","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.4049\/jimmunol.1601629","volume":"198","author":"C Audiger","year":"2017","unstructured":"Audiger, C., Rahman, M. J., Yun, T. J., Tarbell, K. V. & Lesage, S. The importance of dendritic cells in maintaining immune tolerance. J. Immunol. 198, 2223\u20132231 (2017).","journal-title":"J. Immunol."},{"key":"1373_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.adg6425","volume":"380","author":"CC Brown","year":"2023","unstructured":"Brown, C. C. & Rudensky, A. Y. Spatiotemporal regulation of peripheral T cell tolerance. Science 380, 472\u2013478 (2023).","journal-title":"Science"},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","volume":"24","author":"JE Kenison","year":"2024","unstructured":"Kenison, J. E., Stevens, N. A. & Quintana, F. J. Therapeutic induction of antigen-specific immune tolerance. Nat. Rev. Immunol. 24, 338\u2013357 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aav7062","volume":"364","author":"D Sugiura","year":"2019","unstructured":"Sugiura, D. et al. Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses. Science 364, 558\u2013566 (2019).","journal-title":"Science"},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681\u2013691 (2020).","journal-title":"Nat. Cancer"},{"key":"1373_CR15","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dc11-0472","volume":"34","author":"N Giannoukakis","year":"2011","unstructured":"Giannoukakis, N., Phillips, B., Finegold, D., Harnaha, J. & Trucco, M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34, 2026\u20132032 (2011).","journal-title":"Diabetes Care"},{"key":"1373_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.it.2020.11.001","volume":"42","author":"O Morante-Palacios","year":"2021","unstructured":"Morante-Palacios, O., Fondelli, F., Ballestar, E. & Mart\u00ednez-C\u00e1ceres, E. M. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases. Trends Immunol. 42, 59\u201375 (2021).","journal-title":"Trends Immunol."},{"key":"1373_CR17","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1073\/pnas.1820039116","volume":"116","author":"I Zubizarreta","year":"2019","unstructured":"Zubizarreta, I. et al. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc. Natl Acad. Sci. USA 116, 8463\u20138470 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1373_CR18","doi-asserted-by":"publisher","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","volume":"7","author":"H Benham","year":"2015","unstructured":"Benham, H. et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci. Transl. Med. 7, 290ra87 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1373_CR19","doi-asserted-by":"publisher","first-page":"8415","DOI":"10.3390\/ijms22168415","volume":"22","author":"L Passeri","year":"2021","unstructured":"Passeri, L., Marta, F., Bassi, V. & Gregori, S. Tolerogenic dendritic cell-based approaches in autoimmunity. Int. J. Mol. Sci. 22, 8415 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1373_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"1373_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1373_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ Hassett","year":"2021","unstructured":"Hassett, K. J. et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Control. Release 335, 237\u2013246 (2021).","journal-title":"J. Control. Release"},{"key":"1373_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251 (2017).","journal-title":"Nature"},{"key":"1373_CR24","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lor\u00e9, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"},{"key":"1373_CR25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1373_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2311276120","volume":"120","author":"C Wang","year":"2023","unstructured":"Wang, C., Zhao, C., Wang, W., Liu, X. & Deng, H. Biomimetic noncationic lipid nanoparticles for mRNA delivery. Proc. Natl Acad. Sci. USA 120, e2311276120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1373_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo, E. et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat. Commun. 12, 7101 (2021).","journal-title":"Nat. Commun."},{"key":"1373_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145\u2013153 (2021).","journal-title":"Science"},{"key":"1373_CR29","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1373_CR30","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300\u20137306 (2015).","journal-title":"Nano Lett."},{"key":"1373_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","volume":"3","author":"P Zhao","year":"2019","unstructured":"Zhao, P. et al. Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat. Biomed. Eng. 3, 292\u2013305 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"1373_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41422-022-00706-x","volume":"32","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates. Cell Res. 32, 949\u2013952 (2022).","journal-title":"Cell Res."},{"key":"1373_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).","journal-title":"Nat. Commun."},{"key":"1373_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrrheum.2013.7","volume":"9","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea, J. J., Laurence, A. & McInnes, I. B. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat. Rev. Rheumatol. 9, 173\u2013182 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1373_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41584-019-0337-0","volume":"16","author":"KM Kingsmore","year":"2020","unstructured":"Kingsmore, K. M., Grammer, A. C. & Lipsky, P. E. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat. Rev. Rheumatol. 16, 32\u201352 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1373_CR36","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269\u20131275 (2007).","journal-title":"Nat. Protoc."},{"key":"1373_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27948-4","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models. Nat. Commun. 13, 676 (2022).","journal-title":"Nat. Commun."},{"key":"1373_CR38","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nprot.2017.044","volume":"12","author":"S Wirtz","year":"2017","unstructured":"Wirtz, S. et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat. Protoc. 12, 1295\u20131309 (2017).","journal-title":"Nat. Protoc."},{"key":"1373_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41590-018-0134-y","volume":"19","author":"C Tang","year":"2018","unstructured":"Tang, C. et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat. Immunol. 19, 755\u2013765 (2018).","journal-title":"Nat. Immunol."},{"key":"1373_CR40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","volume":"125","author":"G Van Assche","year":"2003","unstructured":"Van Assche, G. et al. Randomized, double-blind comparison of 4\u2009mg\/kg versus 2\u2009mg\/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125, 1025\u20131031 (2003).","journal-title":"Gastroenterology"},{"key":"1373_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1373_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436\u2013443 (2023).","journal-title":"Science"},{"key":"1373_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"1373_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41587-019-0015-4","volume":"37","author":"P Serra","year":"2019","unstructured":"Serra, P. & Santamaria, P. Antigen-specific therapeutic approaches for autoimmunity. Nat. Biotechnol. 37, 238\u2013251 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1373_CR45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nri2153","volume":"7","author":"SD Miller","year":"2007","unstructured":"Miller, S. D., Turley, D. M. & Podojil, J. R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 7, 665\u2013677 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1373_CR46","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2018-eular.2880","volume":"77","author":"Y Kurochkina","year":"2018","unstructured":"Kurochkina, Y. et al. SAT0212 The safety and tolerability of intra-articular injection of tolerogenic dendritic cells in patients with rheumatoid arthritis: the preliminary results. Ann. Rheum. Dis. 77, 966\u2013967 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1373_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","volume":"9","author":"A Jauregui-Amezaga","year":"2015","unstructured":"Jauregui-Amezaga, A. et al. Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn\u2019s disease: a phase I study. J. Crohns Colitis 9, 1071\u20131078 (2015).","journal-title":"J. Crohns Colitis"},{"key":"1373_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147474","volume":"6","author":"S Dong","year":"2021","unstructured":"Dong, S. et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 6, e147474 (2021).","journal-title":"JCI Insight"},{"key":"1373_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin, C., Vo, L. T. & Bluestone, J. A. Treg cell-based therapies: challenges and perspectives. Nat. Rev. Immunol. 20, 158\u2013172 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1373_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139991","volume":"131","author":"T Hirai","year":"2021","unstructured":"Hirai, T. et al. Selective expansion of regulatory T cells using an orthogonal IL-2\/IL-2 receptor system facilitates transplantation tolerance. J. Clin. Invest. 131, e139991 (2021).","journal-title":"J. Clin. Invest."},{"key":"1373_CR51","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.aau2688","volume":"362","author":"JA Bluestone","year":"2018","unstructured":"Bluestone, J. A. & Tang, Q. Treg cells\u2014the next frontier of cell therapy. Science 362, 154\u2013155 (2018).","journal-title":"Science"},{"key":"1373_CR52","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","volume":"8","author":"JA Murray","year":"2023","unstructured":"Murray, J. A. et al. Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial. Lancet Gastroenterol. Hepatol. 8, 735\u2013747 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1373_CR53","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41551-023-01086-2","volume":"7","author":"AC Tremain","year":"2023","unstructured":"Tremain, A. C. et al. Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses. Nat. Biomed. Eng. 7, 1142\u20131155 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"1373_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","volume":"161","author":"CP Kelly","year":"2021","unstructured":"Kelly, C. P. et al. TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study. Gastroenterology 161, 66\u201380.e8 (2021).","journal-title":"Gastroenterology"},{"key":"1373_CR55","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.immuni.2010.03.015","volume":"32","author":"S Tsai","year":"2010","unstructured":"Tsai, S. et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32, 568\u2013580 (2010).","journal-title":"Immunity"},{"key":"1373_CR56","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nnano.2017.56","volume":"12","author":"S Singha","year":"2017","unstructured":"Singha, S. et al. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. Nat. Nanotechnol. 12, 701\u2013710 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"1373_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1373_CR58","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1172\/JCI22996","volume":"115","author":"K Katakura","year":"2005","unstructured":"Katakura, K. et al. Toll-like receptor 9\u2013induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695\u2013702 (2005).","journal-title":"J. Clin. Invest."},{"key":"1373_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.joca.2005.08.015","volume":"14","author":"RW Moskowitz","year":"2006","unstructured":"Moskowitz, R. W. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthr. Cartil. 14, 13\u201329 (2006).","journal-title":"Osteoarthr. Cartil."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01373-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01373-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01373-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:58:07Z","timestamp":1757152687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01373-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01373-0","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}